Moleculin Biotech, Inc. (MBRX)
Automate Your Wheel Strategy on MBRX
With Tiblio's Option Bot, you can configure your own wheel strategy including MBRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MBRX
- Rev/Share 0.0
- Book/Share 0.0045
- PB 59.3997
- Debt/Equity 7.7619
- CurrentRatio 1.3544
- ROIC -1.8351
- MktCap 3772043.0
- FreeCF/Share -2.3248
- PFCF -0.1737
- PE -0.1074
- Debt/Assets 0.0155
- DivYield 0
- ROE -2.9776
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | MBRX | H.C. Wainwright | -- | Buy | -- | $4 | June 9, 2025 |
| Downgrade | MBRX | Maxim Group | Buy | Hold | -- | -- | Feb. 12, 2025 |
News
Moleculin Announces $5.9 Million Public Offering
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
HOUSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the pricing of a public offering consisting of 16,080,000 shares of common stock (or pre-funded warrants in lieu thereof) and Series E warrants to purchase up to 48,240,000 shares of its common stock, at a combined public offering price per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying Series E warrants of $0.37. The Series E warrants will have an exercise …
Read More
Moleculin Participates in Virtual Investor “What This Means” Segment
Published: June 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Globally recognized Oncology Key Opinion Leader, Brian Andrew Van Tine, MD, PhD, discusses the positive topline results from the U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
Read More
Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Access the on-demand webcast here HOUSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the release of its Soft Tissue Sarcoma (STS) Lung Mets KOL Webcast discussing the final data from its U.S. Phase 1B/2 clinical trial evaluating Annamycin as monotherapy for the treatment of soft tissue sarcoma lung metastases (MB-107). For the event, Walter Klemp, Chairman and Chief Executive Officer, and Dr. Paul Waymack, Senior Chief Medical Officer of Moleculin are joined by Key …
Read More
Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral
Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Jenene Thomas - IR, JTC Team, LLC Walter Klemp - Founder, President, CEO and Chairman Paul Waymack - Senior Chief Medical Officer Jonathan Foster - Executive VP & Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Jason McCarthy - Maxim Group Operator Good morning. Welcome to the Moleculin Biotech First Quarter 2025 Update Conference Call and Webcast.
Read More
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Adds nine additional countries to the Company's ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested
Read More
Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET.
Read More
Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Annamycin has the potential to be safer and more effective than current prescribed anthracyclines to treat serious, hard-to-treat cancers Ongoing pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin for the treatment of acute myeloid leukemia (AML); Interim data readout expected in the second half of 2025 HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization approved “naxtarubicin1” for …
Read More
Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically different FDA approved anticancer first line therapies both in vitro and in vivo
Read More
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Moleculin Biotech (MBRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript
Published: March 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Walter Klemp - Chairman and CEO John Paul Waymack - Senior CMO Jonathan Foster - EVP and CFO Conference Call Participants Jonathan Aschoff - Roth Capital Partners Jason McCarthy - Maxim Group Vernon Bernardino - H.C. Wainwright Operator Hello, and welcome to the Moleculin Biotech Fourth Quarter and Full Year 2024 Update Conference Call and Webcast.
Read More
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
HOUSTON , Feb. 25, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has entered into a securities purchase agreement with an institutional investor for the purchase and sale of 3,271,029 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering and warrants to purchase up to 6,542,058 shares of common stock in a concurrent private placement (together with the registered direct offering, the "Offering") at a combined purchase price of $1.07 per …
Read More
Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral
First of many site approvals, including sites in the US, Europe and the Middle East, expected throughout Q1-Q3 2025 Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025 Recently amended protocol accelerates unblinding of preliminary primary efficacy data (CR) and safety/tolerability of the three arms at first 45 subjects, expected in the second half of 2025 HOUSTON , Feb. 11, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat …
Read More
About Moleculin Biotech, Inc. (MBRX)
- IPO Date 2016-06-02
- Website https://www.moleculin.com
- Industry Biotechnology
- CEO Mr. Walter V. Klemp
- Employees 17